title: Comparative randomised clinical trial against glycopeptides supports the use of daptomycin as first-line treatment of complicated skin and soft-tissue infections.
authors: S R
authors: SR
authors: Quist
authors: G
authors: G
authors: Fierlbeck
authors: R A
authors: RA
authors: Seaton
authors: J
authors: J
authors: Loeffler
authors: R L
authors: RL
authors: Chaves
mesh_terms: D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D017576:Daptomycin / Q000009:adverse effects / Q000627:therapeutic use*; D006020:Glycopeptides / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects; D008875:Middle Aged; D018461:Soft Tissue Infections / Q000188:drug therapy* / Q000382:microbiology; D013207:Staphylococcal Skin Infections / Q000188:drug therapy* / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects; D017334:Teicoplanin / Q000627:therapeutic use; D014640:Vancomycin / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D006020:Glycopeptides; D017334:Teicoplanin; D014640:Vancomycin; D017576:Daptomycin